Asthma Clinical Trials 2023

What are the top hospitals conducting asthma research?

Asthma, a common chronic respiratory condition affecting millions worldwide, has prompted some top hospitals to dedicate themselves to finding innovative solutions through clinical trials. In Saint Louis, a renowned research site spearheads this endeavor with six ongoing asthma trials and an impressive track record of 32 completed studies aimed at understanding and managing this condition. Not far behind is the research site in Newport Beach, which boasts five active asthma trials and has conducted 21 previous investigations since their first recorded trial in 2011.

Meanwhile, the GSK Investigational Site located in Orlando is making considerable strides towards combating asthma with five ongoing clinical trials and a commendable history of 14 past studies dedicated to unraveling its complexities dating back to their initial trial in 2001. Similarly committed to advancing our knowledge of asthma is the research site based in Oklahoma City, where researchers are conducting five active clinical trials while having successfully completed an astounding tally of 42 experiments since embarking on their inaugural investigation in 2006.

Last but not least, San Antonio's research site plays a vital role as well by engaging in five current asthma clinical trials and contributing significantly through their extensive collection of 45 previously held investigations dating back fifteen years ago. These exceptional hospitals collectively strive towards enhancing our understanding of asthma risks factors, triggers mechanisms involved thus providing invaluable insights into developing more effective treatments for those living with respiratory conditions.

Through these critical endeavors undertaken by leading medical institutions across various locations nationwide comes hope that advancements made today will pave the way for better management strategies tomorrow—ultimately improving quality of life for countless individuals affected by this widespread condition.

Which are the best cities for asthma clinical trials?

When it comes to asthma clinical trials, several cities emerge as leading hubs for research and advancement. Miami, Florida boasts 24 active trials focusing on treatments like 75 mg BID, Dupilumab, and RPT193 400 mg. New York, New York closely follows with 18 ongoing studies exploring interventions such as the Controlling Asthma Program for Adolescents (CAMP Air) and GSK3511294 (Depemokimab). Saint Louis, Missouri is also a significant player with 16 trials investigating Tezepelumab and asthma reliever therapies. Additionally, Boston, Massachusetts and Toronto, Ontario have notable contributions to this field with their respective active trials centered around medications like Dupilumab and Vitamin Dmg. New York, New York closely follows with 18 ongoing studies exploring interventions such as the Controlling Asthma Program for Adolescents (CAMP Air) and GSK3511294 (Depemokimab). Saint Louis, Missouri is also a significant player with 16 trials investigating Tezepelumab and asthma reliever therapies. Additionally, Boston, Massachusetts and Toronto, Ontario have notable contributions to this field with their respective active trials centered around medications like Dupilumab and Vitamin D supplementation. These cities collectively offer valuable opportunities for individuals seeking participation in cutting-edge asthma clinical trials that may bring about improved management strategies in the future.

Which are the top treatments for asthma being explored in clinical trials?

When it comes to advancements in asthma treatment, several potential breakthroughs are currently being explored in clinical trials. Two standout contenders are Dupilumab and Tezepelumab, both participating in five active trials for asthma. Since their initial listings in 2011, they have accumulated a respectable 18 and 13 all-time asthma trials respectively. Additionally, the Community Health Navigator Program has caught attention with three ongoing trials since its introduction in 2021. Another promising prospect is GSK3511294 (Depemokimab), which also joins the ranks of three active and four all-time asthma trials after its recent debut this year. These innovative treatments provide hope for better management and control of this chronic respiratory condition that affects millions around the world.

What are the most recent clinical trials for asthma?

Recent clinical trials for asthma have provided promising insights into potential treatment options. These include TEV-56248, a low-dose medication currently in Phase 3 trials, and Tezepelumab, another Phase 3 candidate that has shown positive results. Additionally, RPT193 at a dose of 400 mg is being evaluated in Phase 2 studies as a prospective therapy for asthma patients. Another interesting trial explores the impact of maintaining overall health on managing asthma symptoms. Lastly, participants receiving FF/UMEC/VI are being studied to assess the effectiveness of this combination therapy in treating asthma. These ongoing trials offer hope for improved therapies and better quality of life for individuals living with asthma.

What asthma clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of asthma research, bringing hope for improved treatments. Notably, a trial sponsored by Cipla Ltd. investigated the efficacy of Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg and concluded in April 2022. Another study conducted by Cerecor Inc., exploring AVTX-002's potential, wrapped up in February 2022. Additionally, Dupilumab was assessed as a treatment option in two separate trials sponsored by the University of Michiganf asthma research, bringing hope for improved treatments. Notably, a trial sponsored by Cipla Ltd. investigated the efficacy of Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg and concluded in April 2022. Another study conducted by Cerecor Inc., exploring AVTX-002's potential, wrapped up in February 2022. Additionally, Dupilumab was assessed as a treatment option in two separate trials sponsored by the University of Michigan and AstraZeneca, both completed in February 2022. These advancements highlight ongoing efforts to address asthma management and enhance patient outcomes.